Copenhagen - Delayed Quote ? DKK Bavarian Nordic A/S (BAVA.CO) Follow Compare 204.00 +4.00 (+2.00%) At close: November 7 at 4:59 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Bavarian Nordic’s mpox vaccine to be trialled in pregnant women and infants Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population. Clinical Trials Arena ? 18 hours ago BAVA.CO +2.00% Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year? Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year. Zacks ? 8 days ago BAVA.CO +2.00% DARE Bavarian eyes mpox vaccine label expansion to include toddlers, kickstarts Phase II trial The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children between two and 11 years of age. Clinical Trials Arena ? 9 days ago BAVA.CO +2.00% First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age. COPENHAGEN, Denmark, October 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN? mpox/smallpox vaccine in children 2 to 11 years of age. The first children have now been vaccinated in the study, which is currently enrolling in the Democratic Republic of Congo (DRC) with plans also to include sites i GlobeNewswire ? 10 days ago BVNKF BVNRY Is Bavarian Nordic (BVNRY) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Zacks ? 13 days ago BAVA.CO +2.00% Bavarian Nordic’s mpox vaccine equally effective in teens as adults Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study. Clinical Trials Arena ? 21 days ago BAVA.CO +2.00% Should Value Investors Buy Bavarian Nordic (BVNRY) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Zacks ? 29 days ago BAVA.CO +2.00% Bavarian Nordic (BVNRY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Bavarian Nordic (BVNRY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. Zacks ? last month BAVA.CO +2.00% UNICEF secures one million mpox vaccines for Africa Bavarian Nordic has already said it would prioritise mpox vaccine production to fulfil orders this year. Pharmaceutical Technology ? last month BAVA.CO +2.00% Bavarian Nordic Upgrades its Financial Guidance for 2024 COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured, combined with improved performance in Travel Health, as well as other parts of the business, Bavarian Nordic now expects revenue between DKK 5,400 million and DKK 5,800 million and EBITDA between DKK 1,450 million and DKK 1,700 million. Revenue from the Travel Health business is now expected at approximate GlobeNewswire ? last month BVNKF BVNRY Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN? mpox vaccine for countries in Africa impacted by the mpox outbreak. Under the agreement, UNICEF will procure 1 million doses of the vaccine which includes the 500,000 doses that were committed by Gavi and announced on September 18, 2024. As pa GlobeNewswire ? last month BVNKF BVNRY Bavarian Nordic gains US contract for additional mpox vaccine The vaccine bulk manufacturing is scheduled for 2025 with the delivery of the freeze-dried doses set for 2026. Pharmaceutical Technology ? last month BAVA.CO +2.00% Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines Contract will further strengthen the U.S, bulk vaccine inventory and secure additional freeze-dried dosesDeliveries planned for 2025 and beyond COPENHAGEN, Denmark, September 24, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has received an additional order valued at USD 63 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Servic GlobeNewswire ? last month BVNKF BVNRY Are Investors Undervaluing Bavarian Nordic (BVNRY) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Zacks ? last month BAVA.CO +2.00% EMA approves Bavarian Nordic’s mpox vaccine for teenagers Data showed non-inferiority of immune response between adults and adolescents with Imvanex. Pharmaceutical Technology ? last month BAVA.CO +2.00% Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger population COPENHAGEN, Denmark, September 19, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for IMVANEX? (MVA-BN) smallpox and mpox vaccine, exten GlobeNewswire ? last month BVNKF BVNRY Gavi to obtain 500,000 mpox vaccine doses from Bavarian Nordic The doses of the MVA-BN mpox vaccine will be supplied to African countries. Pharmaceutical Technology ? last month BAVA.CO +2.00% Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa The advance purchase agreement (APA) will be funded by Gavi’s First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health emergencies.Availability of all 500,000 doses has been secured for 2024. COPENHAGEN, Denmark and GENEVA, Switzerland, September 18, 2024 – Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN? mpox vacc GlobeNewswire ? last month BVNKF BVNRY UK Secures Additional Doses Of Bavarian Nordic Mpox Vaccine To Combat New Variant Threat The U.K. government has secured over 150,000 doses of the mpox vaccine from Bavarian Nordic A/S (OTC:BVNRY) (OTC:BVNKF) to strengthen the nation's defenses against clade I mpox. The vaccines will be distributed across the country, with the National Health Service (NHS) prioritizing individuals at higher risk of exposure to the virus. Almost two weeks ago, the European Commission said around 100,000 mpox vaccine doses arrived in the Democratic Republic of Congo (DRC), making these the first vacci Benzinga ? last month BAVA.CO +2.00% Canada's Only Single-Dose Cholera Vaccine Available Nationwide TORONTO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bavarian Nordic, a leading global supplier of travel vaccines, today announced the commercial availability of VAXCHORA?—the only single-dose oral vaccine approved in Canada to protect against cholera, a sudden and serious intestinal infection marked by acute watery diarrhea. For approximately 1 in 10 people infected with cholera, a severe presentation of cholera can rapidly cause severe dehydration and death if left untreated1. Cholera is endemic to ap GlobeNewswire ? last month BVNKF BVNRY Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index Return BAVA.CO OMX Copenhagen 25 Index YTD +14.96% +1.77% 1-Year +42.96% +13.30% 3-Year -29.63% -5.20%
